{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-065229","form_type":"8-K","ticker":null,"cik":"0001403708","company_name":"Evoke Pharma Inc","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.266385+00:00","generated_at":"2026-06-01T07:56:23.735571+00:00","sec_items":["5.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Evoke Pharma appoints new CFO, shareholders approve share increase and reverse split authority","bullets":["Mark A. Kowieski appointed CFO effective May 22, 2024; annual base salary $390,000, target bonus 40%.","CEO Matthew D'Onofrio base salary raised to $615,000, target bonus to 60%.","Shareholders approved increase in authorized common shares from 50M to 100M.","Shareholders approved amendment to 2013 Equity Incentive Award Plan, adding 4M shares plus evergreen provision (up to 6% of outstanding annually).","Shareholders granted Board authority to effect reverse stock split within 1 year, range 1:2 to 1:20."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-065229","json":"https://secwatch.observer/filing/0000950170-24-065229.json","markdown":"https://secwatch.observer/filing/0000950170-24-065229.md","text":"https://secwatch.observer/filing/0000950170-24-065229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024065229/0000950170-24-065229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024065229/evok-20240522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:56:23.735571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"191e779cf6","claim":"Mark A. Kowieski was appointed as Chief Financial Officer at Evoke Pharma Inc.","evidence_excerpt":"On May 22, 2024, the Board appointed Mr. Kowieski, age 47, as Chief Financial Officer (\"CFO\") of Evoke Pharma, Inc. (the \"Company\") effective May 22, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024065229/0000950170-24-065229-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}